24.63
1.28%
-0.32
Dopo l'orario di chiusura:
24.63
Precedente Chiudi:
$24.95
Aprire:
$24.88
Volume 24 ore:
677.45K
Capitalizzazione di mercato:
$3.13B
Reddito:
$2.74B
Utile/perdita netta:
$-11.90M
Rapporto P/E:
-43.98
EPS:
-0.56
Flusso di cassa netto:
$205.00M
1 W Prestazione:
-3.41%
1M Prestazione:
-14.72%
6M Prestazione:
+8.74%
1 anno Prestazione:
-37.44%
Surgery Partners Inc Stock (SGRY) Company Profile
Nome
Surgery Partners Inc
Settore
Industria
Telefono
615-234-5900
Indirizzo
310 Seven Springs Way, Suite 500, Brentwood, TN
Surgery Partners Inc Stock (SGRY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-11-14 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-05-12 | Iniziato | Mizuho | Buy |
2023-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
2022-11-23 | Reiterato | RBC Capital Mkts | Outperform |
2022-06-15 | Downgrade | BofA Securities | Buy → Neutral |
2022-01-10 | Ripresa | Citigroup | Buy |
2021-11-30 | Iniziato | Barclays | Overweight |
2021-11-29 | Aggiornamento | Stifel | Hold → Buy |
2021-11-01 | Iniziato | JP Morgan | Neutral |
2021-10-18 | Iniziato | SVB Leerink | Outperform |
2021-09-10 | Iniziato | Cowen | Market Perform |
2021-06-23 | Ripresa | Stifel | Hold |
2020-09-17 | Reiterato | The Benchmark Company | Buy |
2020-04-27 | Aggiornamento | The Benchmark Company | Hold → Buy |
2020-03-03 | Downgrade | The Benchmark Company | Buy → Hold |
2020-01-14 | Reiterato | The Benchmark Company | Buy |
2018-11-16 | Iniziato | UBS | Neutral |
2018-09-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2018-06-28 | Aggiornamento | Stifel | Sell → Hold |
2018-01-30 | Reiterato | The Benchmark Company | Buy |
2017-11-01 | Downgrade | BofA/Merrill | Buy → Neutral |
2017-08-09 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
2017-08-09 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
2017-08-09 | Downgrade | Stifel | Hold → Sell |
2017-04-24 | Reiterato | Stifel | Hold |
2017-03-10 | Downgrade | Stifel | Buy → Hold |
2017-01-31 | Iniziato | The Benchmark Company | Buy |
2016-06-10 | Iniziato | KeyBanc Capital Mkts | Overweight |
2016-03-14 | Reiterato | RBC Capital Mkts | Outperform |
2015-10-27 | Iniziato | Stifel | Buy |
2015-10-26 | Iniziato | RBC Capital Mkts | Outperform |
2015-10-26 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Surgery Partners Inc Borsa (SGRY) Ultime notizie
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
Zacks Investment Research
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
GlobeNewswire Inc.
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
Zacks Investment Research
Surgery Partners, Inc. Announces Pricing of New Senior Notes Offering
GlobeNewswire Inc.
Surgery Partners, Inc. Announces New Senior Notes Offering
GlobeNewswire Inc.
Surgery Partners Inc Azioni (SGRY) Dati Finanziari
Surgery Partners Inc (SGRY) Reddito 2024
SGRY ha riportato un ricavo (TTM) di $2.74 miliardi per il trimestre terminato il 2023-12-31, un +8.03% salita anno su anno.
Surgery Partners Inc (SGRY) Reddito netto 2024
SGRY l'utile netto (TTM) è stato di -$11.90 milioni per il trimestre terminato il 2023-12-31, un +78.21% aumento anno su anno.
Surgery Partners Inc (SGRY) Flusso di cassa 2024
SGRY ha registrato un flusso di cassa disponibile (TTM) di $205.00 milioni per il trimestre conclusosi con 2023-12-31, un +162.15% aumento anno su anno.
Surgery Partners Inc (SGRY) Utile per azione 2024
L'utile per azione (TTM) di SGRY è stato pari a -$0.10 per il trimestre terminato il 2023-12-31, un +82.76% crescita anno su anno.
Surgery Partners Inc Azioni (SGRY) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Doherty David T | Chief Financial Officer |
Mar 14 '24 |
Sale |
28.59 |
721 |
20,613 |
95,719 |
Evans Jason Eric | Chief Executive Officer |
Mar 13 '24 |
Sale |
29.71 |
4,840 |
143,796 |
459,670 |
Owens Bradley R. | National Group President |
Mar 12 '24 |
Sale |
29.82 |
2,783 |
82,989 |
78,338 |
Baldock Jennifer | Chief Admin & Dev Officer |
Mar 12 '24 |
Sale |
29.74 |
922 |
27,420 |
183,644 |
TAPARO ANTHONY | Chief Growth Officer |
Mar 12 '24 |
Sale |
29.87 |
787 |
23,508 |
102,321 |
Burkhalter Danielle | Chief Human Resources Officer |
Mar 12 '24 |
Sale |
29.74 |
111 |
3,301 |
36,354 |
Evans Jason Eric | Chief Executive Officer |
Mar 11 '24 |
Sale |
29.44 |
1,984 |
58,409 |
464,510 |
Baldock Jennifer | Chief Admin & Dev Officer |
Mar 11 '24 |
Sale |
29.70 |
675 |
20,048 |
184,566 |
TAPARO ANTHONY | Chief Growth Officer |
Mar 11 '24 |
Sale |
29.54 |
651 |
19,231 |
103,108 |
Owens Bradley R. | National Group President |
Mar 11 '24 |
Sale |
29.49 |
632 |
18,638 |
81,121 |
Capitalizzazione:
|
Volume (24 ore):